Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) shares gapped up before the market opened on Monday. The stock had previously closed at $12.30, but opened at $12.72. Bayer Aktiengesellschaft shares last traded at $12.71, with a volume of 50,995 shares changing hands.
Analysts Set New Price Targets
Several brokerages have recently issued reports on BAYRY. Zacks Research raised shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a report on Friday, July 10th. Deutsche Bank Aktiengesellschaft upgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a report on Thursday, July 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy”.
View Our Latest Research Report on Bayer Aktiengesellschaft
Bayer Aktiengesellschaft Stock Performance
The firm has a market cap of $49.83 billion, a price-to-earnings ratio of -24.86, a price-to-earnings-growth ratio of 1.86 and a beta of 0.57. The stock has a 50-day moving average of $13.53 and a 200-day moving average of $12.64. The company has a debt-to-equity ratio of 1.05, a quick ratio of 0.67 and a current ratio of 1.04.
Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.23 by $0.06. The business had revenue of $12.53 billion for the quarter, compared to analyst estimates of $12.31 billion. Bayer Aktiengesellschaft had a positive return on equity of 16.77% and a negative net margin of 3.80%. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. As a group, analysts anticipate that Bayer Aktiengesellschaft will post 1.27 EPS for the current fiscal year.
Bayer Aktiengesellschaft Company Profile
Bayer Aktiengesellschaft is a Germany-based life sciences company headquartered in Leverkusen. Founded in 1863 by Friedrich Bayer and Johann Friedrich Weskott, the company develops products in health care and agriculture and serves customers in markets around the world.
Bayer operates through three primary businesses: Pharmaceuticals, Consumer Health and Crop Science. Its Pharmaceuticals segment develops prescription medicines in areas such as cardiovascular disease, women’s health, oncology, hematology and specialty therapies.
Read More
- Five stocks we like better than Bayer Aktiengesellschaft
- Not All Tech Is Getting Crushed: 5 Names Holding Up Through the AI Sell-Off
- Actively Managed ETFs Are Giving In to the Price War—To the Benefit of Investors
- Valero’s Windfall Quarter Meets Washington’s Push for Cheaper Diesel
- 4 Small-Cap Stocks With Paths to Recovery After the Fed’s September Rate Hike
Receive News & Ratings for Bayer Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer Aktiengesellschaft and related companies with MarketBeat.com's FREE daily email newsletter.
